Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Antiparkinsonian

or Beta Blocker

or Phenethylamine

Use the filters below to narrow your results.

None (26) · Akineton (1) · Apokyn (1) · Artane (1) · Azilect (1) · Betapace (1) · Brevibloc (1) · Bystolic (1) · Cogentin (1) · Comtan (1) · Corgard (1) · Dostinex (1) · Eldepryl (1) · Inderal (1) · Lopressor (tartrate), Toprol XL (succinate) (1) · Neupro (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Ongentys (1) · Parlodel (1) · Sinemet (1) · Symmetrel (1) · Tasmar (1) · Xadago (1) · Zebeta (1)

None (3) · 5-HT2A agonist (12) · 5-HT2A agonist; long duration (1) · 5-HT2A agonist; MAO inhibitor (1) · 5-HT2A agonist; milder than other 2C-x (1) · 5-HT2A partial agonist (1) · Cardioselective β1-adrenergic antagonist. Selectivity is dose-dependent and partially lost at higher doses. (1) · Central and peripheral COMT inhibitor (1) · D1/D2/D3 receptor agonist (1) · D2 agonist; D1 partial agonist (1) · D2 receptor agonist (1) · Dopamine precursor (1) · Dopamine precursor + DOPA decarboxylase inhibitor (1) · Extremely potent 5-HT2A agonist; vasoconstrictor (1) · Extremely potent 5-HT2A agonist; very long duration (1) · Highly β1-selective adrenergic antagonist. Greater selectivity than metoprolol or atenolol. (1) · Irreversible selective MAO-B inhibitor (2) · MAO-B inhibitor; sodium channel blocker; glutamate release inhibitor (1) · Muscarinic receptor antagonist (1) · Muscarinic receptor antagonist; dopamine reuptake inhibitor (1) · NMDA antagonist; dopamine releasing agent (1) · Non-selective competitive antagonist at β1 and β2 adrenergic receptors. Lipophilic; significant blood–brain barrier penetration, accounting for its CNS effects. (1) · Non-selective dopamine receptor agonist (1) · Once-daily COMT inhibitor (1) · Peripheral COMT inhibitor (1) · Potent 5-HT2A agonist (5) · Potent 5-HT2A agonist; no oral activity (1) · Potent 5-HT2A agonist; very long duration (1) · Selective M1 muscarinic antagonist (1) · The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism. (1) · Very potent 5-HT2A agonist; long duration (1)

None (45) · '"`UNIQ--vote-000004F5-QINU`"', '"`UNIQ--vote-000004F6-QINU`"', '"`UNIQ--vote-000004F7-QINU`"', '"`UNIQ--vote-000004F8-QINU`"', '"`UNIQ--vote-000004F9-QINU`"' (1) · '"`UNIQ--vote-0000059D-QINU`"' (1) · '"`UNIQ--vote-000005E7-QINU`"', '"`UNIQ--vote-000005E8-QINU`"', '"`UNIQ--vote-000005E9-QINU`"', '"`UNIQ--vote-000005EA-QINU`"', '"`UNIQ--vote-000005EB-QINU`"' (1) · '"`UNIQ--vote-00000636-QINU`"', '"`UNIQ--vote-00000637-QINU`"', '"`UNIQ--vote-00000638-QINU`"' (1)

None (45) · 10–40 mg (situational anxiety); 40 mg BID (HTN) (1) · 2.5–5 mg daily (HTN); 1.25 mg daily (HFrEF, slow titration) (1) · 25–50 mg BID (tartrate); 25–100 mg daily (succinate); 12.5 mg daily in HFrEF (1) · 5 mg daily (1)

None (45) · 10, 20, 40, 60, 80 mg tabs; 60/80/120/160 mg ER caps; 1 mg/mL IV (1) · 2.5, 5, 10, 20 mg tabs (1) · 5, 10 mg tabs (1) · Tartrate: 25, 50, 100 mg tabs; 1 mg/mL IV. Succinate ER: 25, 50, 100, 200 mg. (1)

None (45) · 20 mg/d (1) · 40 mg/d (1) · 400 mg/d (1) · 640 mg/d (HTN); 240 mg/d (migraine) (1)

None (44) · insufflated (1) · IV (2) · Oral (5) · PR (1)

None (44) · 1–2 h (2) · 1–2 h (PO), immediate (IV) (1) · 1–2 h (PO); immediate (IV) (1) · 45-75 min (oral) (1)

None (44) · 24 h (2) · 4-8 h (1) · 6–12 h (IR); 24 h (ER) (1) · 6–12 h (tartrate); 24 h (succinate) (1)

None (44) · 3–6 h (1) · 3–7 h (1) · 9–12 h (1) · Not well characterized (1) · ~10 h (CYP2D6 extensive metabolizers); up to 31 h (poor metabolizers) (1)

None (44) · Not well characterized (1) · ~12% (extensive metabolizers); ~96% (poor metabolizers) (1) · ~25% (extensive hepatic first-pass) (1) · ~50% (1) · ~90% (low first-pass) (1)

None (44) · Category C (4) · Not established (1)

None (44) · Rx-only in US (4) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)